Alexei Kharitonenkov


Affiliation: Eli Lilly and Company
Country: USA


  1. Kharitonenkov A, Wroblewski V, Koester A, Chen Y, Clutinger C, Tigno X, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148:774-81 pubmed
    ..These data support the development of FGF-21 for the treatment of diabetes and other metabolic diseases. ..
  2. Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol. 2009;9:805-10 pubmed publisher
  3. Kharitonenkov A, Shiyanova T, Koester A, Ford A, Micanovic R, Galbreath E, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627-35 pubmed
    ..Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes. ..
  4. Kharitonenkov A, Dunbar J, Bina H, Bright S, Moyers J, Zhang C, et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol. 2008;215:1-7 pubmed
    ..All together, these results indicate that betaKlotho and FGFRs form the cognate FGF-21 receptor complex, mediating FGF-21 cellular specificity and physiological effects. ..
  5. Kharitonenkov A, Beals J, Micanovic R, Strifler B, Rathnachalam R, Wroblewski V, et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE. 2013;8:e58575 pubmed publisher